Ruben Mylvaganam

Dr. Ruben Mylvaganam

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 December 2021 in European Respiratory Review
Verified
Journal Article
Open access
PDF file
RMRuben Mylvaganam
Ruben Mylvaganam
JBJoseph I. Bailey
Joseph I. Bailey
JSJacob I. Sznajder
Jacob I. Sznajder
MSMarc A. Sala
Marc A. Sala
Acute manifestations of SARS-CoV-2 infection continue to impact the lives of many across the world. Post-acute sequelae of coronavirus disease 2019 (COVID-19) may affect 10–30% of survivors of COVID-19, and post-acute sequelae of COVID-19 (PASC)-pulmonary fibrosis is a long-term outcome associated with major morbidity. Data from prior coronavirus outbreaks (severe acute respiratory syndrome and Middle East respiratory syndrome) suggest that pulmonary fibrosis will contribute to long-term respiratory morbidity, suggesting that PASC-pulmonary fibrosis should be thoroughly screened for through pulmonary function testing and cross-sectional imaging. As data accumulates on the unique pathobiologic mechanisms underlying critical COVID-19, a focus on corollaries to the subacute and chronic profibrotic phenotype must be sought as well. Key aspects of acute COVID-19 pathobiology that may account for increased rates of pulmonary fibrosis include monocyte/macrophage–T-cell circuits, profibrotic RNA transcriptomics, protracted elevated levels of inflammatory cytokines, and duration of illness and ventilation. Mechanistic understanding of PASC-pulmonary fibrosis will be central in determining therapeutic options and will ultimately play a role in transplant considerations. Well-designed cohort studies and prospective clinical registries are needed. Clinicians, researchers and healthcare systems must actively address this complication of PASC to minimise disability, maximise quality of life and confront a post-COVID-19 global health crisis.

1 April 2021 in Diagnostic Microbiology and Infectious Disease
Verified
Journal Article
Closed access
CWCeleste Witting
Celeste Witting
JQJessica Quaggin-Smith
Jessica Quaggin-Smith
RMRuben Mylvaganam
Ruben Mylvaganam
GPGraham Peigh
Graham Peigh
MAMichael Angarone
Michael Angarone
JFJames D. Flaherty
James D. Flaherty

1 January 2021 in Pulmonary Circulation
Verified
Journal Article
Open access
PDF file
RMRuben Mylvaganam
Ruben Mylvaganam
RARyan Avery
Ryan Avery
IGIsaac Goldberg
Isaac Goldberg
CMCourtney Makowski
Courtney Makowski
RKRavi Kalhan
Ravi Kalhan
MCMichael J. Cuttica
Michael J. Cuttica
Immunologic risk factors contribute to endothelial dysfunction and development of pulmonary vascular disease. Immune checkpoint inhibitors, used as immunotherapies for malignancies, have a wide range of reported immune‐related adverse events. We retrospectively describe the impact of immune checkpoint inhibitors on the development of pulmonary vascular injury and right ventricular dysfunction as compared across both computed tomography and transthoracic echocardiography. Twenty‐four of 389 patients treated with immune checkpoint inhibitors at a single academic center between 2015 and 2019 were evaluated. Thirteen (54%) patients were treated with anti‐programmed cell death receptor 1 (PD‐1), 8 (33%) with anti‐programmed death receptor ligand 1 (PD‐L1) therapy, and 3 (13%) with combination anti‐PD‐1 and anti‐cytotoxic T‐lymphocyte‐associated antigen 4 (CTLA‐4) therapy. At a median of 85 days of immune checkpoint inhibitor therapy, RVfwLS significantly increased from –20.6% to –16.7% (p = 0.002). After a median of 59 days of immune checkpoint inhibitor therapy, median pulmonary artery to aorta ratio worsened from 0.83 to 0.89 (p = 0.03). There was an correlation of duration of immune checkpoint inhibitor therapy (β = –0.574, p = 0.003) with percent change in RVfwLS. Patients who received anti‐PD‐1 therapy (β = –0.796, p = 0.001) showed the greatest correlation of duration of immune checkpoint inhibitor therapy with percent change in RVfwLS. Exposure to immune checkpoint inhibitors are associated with RV dysfunction and vascular changes as measured by strain and computed tomography, respectively.

18 August 2023 in Journal of Pain and Symptom Management
Verified
Journal Article
Open access
MRMichaella M. Reif
Michaella M. Reif
KSKatharine E. Secunda
Katharine E. Secunda
JCJustin T. Clapp
Justin T. Clapp
EVElizabeth M. Viglianti
Elizabeth M. Viglianti
RMRuben Mylvaganam
Ruben Mylvaganam
JKJacqueline M. Kruser
Jacqueline M. Kruser
The phrase "goals of care" (GOC) is common in serious illness care, yet it lacks clarity and consistency. Understanding how GOC is used across healthcare contexts is an opportunity to identify and mitigate root causes of serious illness miscommunication. We sought to characterize frontline palliative and critical care clinicians' understanding and use of the phrase GOC in clinical practice. We conducted a secondary qualitative thematic analysis of focus group transcripts (n = 10), gathered as part of a parent study of care delivery for patients with respiratory failure. Participants (n = 59) were members of the palliative and critical care interprofessional teams at two academic medical centers. Clinicians primarily use GOC as a shorthand signal among team members to indicate a patient is nearing the end of life. This signal can also indicate conflict with patients and families when clinicians' expectations-typically an expected "transition" toward a different type of care-are not met. Clinicians distinguish their clinical use of GOC from an "ideal" meaning of the phrase, which is broader than end of life and focused on patients' values. Palliative care specialists encourage other clinicians to shift toward the "ideal" GOC concept in clinical practice. Frontline palliative and critical care clinicians understand a duality in GOC, as an idealized concept and as an expeditious signal for clinical care. Our findings suggest ambiguous phrases like GOC persist because of unmet needs for better ways to discuss and address diverse and complex priorities for patients with serious illness.

1 April 2017 in Seminars in Respiratory and Critical Care Medicine
Verified
Journal Article
Closed access
PDF file
RMRuben Mylvaganam
Ruben Mylvaganam
SDSakshi Dua
Sakshi Dua
CNCatherine Nelson-Piercy
Catherine Nelson-Piercy
AMAditi Mathur
Aditi Mathur
Interstitial lung disease (ILD) is an inflammatory and fibrotic infiltrative process of the lung that is often associated with collagen vascular disease in women. Untreated, it results in collagen deposition in the lung interstitium that can lead to a slow suffocating death. Pregnancy planning is often not discussed with women who have ILD due to concerns about potentially aggravating the disease process, or due to lack of knowledge about the safety of medications used to treat ILD. With improved understanding of the pathophysiology of both autoimmune disease and ILD, it has become clear that safe, planned pregnancies are possible in most women with ILD. In this article, our aim is to review diagnosis, treatment, and disease course of ILD in women who are planning a pregnancy or are pregnant. Better understanding of the disease process and knowledge of safe treatments will likely lead to improved pregnancy planning in women with ILD.

12 February 2023 in Journal of Thrombosis and Thrombolysis
Verified
Journal Article
Closed access
PDF file
RMRuben Mylvaganam
Ruben Mylvaganam
RLRomy Lawrence
Romy Lawrence
IGIsaac Goldberg
Isaac Goldberg
FRFarbod Rahaghi
Farbod Rahaghi
SCStephen Chiu
Stephen Chiu
MCMichael J. Cuttica
Michael J. Cuttica